Finding our way through the labyrinth of dementia biomarkers
Eur J Nucl Med Mol Imaging
.
2021 Jul;48(8):2320-2324.
doi: 10.1007/s00259-021-05301-7.
Authors
Gaël Chételat
1
,
Javier Arbizu
2
,
Henryk Barthel
3
,
Valentina Garibotto
4
,
Adriaan A Lammertsma
5
6
,
Ian Law
7
,
Silvia Morbelli
8
,
Elsmarieke van de Giessen
9
,
Alexander Drzezga
10
11
12
Affiliations
1
Normandie Univ, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Cyceron, 14000, Caen, France. chetelat@cyceron.fr.
2
Department of Nuclear Medicine, University of Navarra Clinic, Pamplona, Spain.
3
Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany.
4
Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals and NIMTlab, Geneva University, Geneva, Switzerland.
5
Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.
6
Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
7
Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
8
Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
9
AMC Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
10
Department of Nuclear Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
11
German Center for Neurodegenerative Diseases (DZNE), Bonn/Köln, Germany.
12
Institute of Neuroscience and Medicine, Molecular Organization of the Brain (INM-2), Forschungzentrum Jülich, Jülich, Germany.
PMID:
33876260
DOI:
10.1007/s00259-021-05301-7
No abstract available
Publication types
Editorial
MeSH terms
Biomarkers
Dementia* / diagnostic imaging
Humans
Substances
Biomarkers